The 'FIDO' strategy behind Onyx deal

Onyx Pharmaceuticals' five-year R&D agreement with Miles Inc. illustrates the value research boutiques can garner from their skills, according to Hollings Renton, president and CEO.

The deal, worth up to $75 million, will focus on discovery of small molecule drugs that treat disease by inhibiting Ras intracellular signaling pathways and curbing cancerous cell growth.